Caribou Biosciences Inc (CRBU) News

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...

Form 8-K - Current report

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

-- Fast Track designation is designed to expedite clinical development and regulatory review timelines...

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data...

Form 8-K - Current report